Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jerome Ritz, M.D.

Co-Author

This page shows the publications co-authored by Jerome Ritz and Stuart Schlossman.
Connection Strength

1.577
  1. Characterization of functional surface structures on human natural killer cells. Adv Immunol. 1988; 42:181-211.
    View in: PubMed
    Score: 0.096
  2. In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. Haematol Blood Transfus. 1983; 28:117-23.
    View in: PubMed
    Score: 0.068
  3. Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet. 1982 Jul 10; 2(8289):60-3.
    View in: PubMed
    Score: 0.066
  4. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood. 1982 Jan; 59(1):1-11.
    View in: PubMed
    Score: 0.063
  5. Use of monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia. Cancer Res. 1981 Nov; 41(11 Pt 2):4771-5.
    View in: PubMed
    Score: 0.063
  6. Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood. 1981 Sep; 58(3):648-52.
    View in: PubMed
    Score: 0.062
  7. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981 Jul; 58(1):141-52.
    View in: PubMed
    Score: 0.061
  8. Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. J Immunol. 1980 Oct; 125(4):1506-14.
    View in: PubMed
    Score: 0.058
  9. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature. 1980 Feb 07; 283(5747):583-5.
    View in: PubMed
    Score: 0.055
  10. CD antigens 1993. Immunol Today. 1994 Mar; 15(3):98-9.
    View in: PubMed
    Score: 0.037
  11. CD antigens 1993. Blood. 1994 Feb 15; 83(4):879-80.
    View in: PubMed
    Score: 0.037
  12. CD antigens 1993. J Immunol. 1994 Jan 01; 152(1):1-2.
    View in: PubMed
    Score: 0.036
  13. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A. 1990 Mar; 87(6):2274-8.
    View in: PubMed
    Score: 0.028
  14. CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. Nature. 1989 Sep 14; 341(6238):159-62.
    View in: PubMed
    Score: 0.027
  15. Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells. J Immunol. 1989 Jun 01; 142(11):4105-12.
    View in: PubMed
    Score: 0.026
  16. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant. 1989 May; 4(3):239-45.
    View in: PubMed
    Score: 0.026
  17. Induction of natural killer effectors from human thymus with recombinant IL-2. J Immunol. 1988 May 15; 140(10):3660-7.
    View in: PubMed
    Score: 0.025
  18. Enhancement of natural killer function through activation of the T11 E rosette receptor. J Clin Invest. 1987 Jan; 79(1):305-8.
    View in: PubMed
    Score: 0.022
  19. Monoclonal antibodies: their use in bone marrow transplantation. Prog Hematol. 1987; 15:137-81.
    View in: PubMed
    Score: 0.022
  20. Activation of natural killer function through the T11/E rosette receptor. Haematol Blood Transfus. 1987; 31:347-50.
    View in: PubMed
    Score: 0.022
  21. Function of the LFA-1 and T4 molecules in the direct activation of resting human B lymphocytes by T lymphocytes. Eur J Immunol. 1986 Dec; 16(12):1539-43.
    View in: PubMed
    Score: 0.022
  22. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med. 1986 Jul 01; 164(1):351-6.
    View in: PubMed
    Score: 0.022
  23. Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement. A quantitative and functional analysis. Transplantation. 1986 Jul; 42(1):73-80.
    View in: PubMed
    Score: 0.022
  24. Expression of the NKTa clonotype in a series of human natural killer clones with identical cytotoxic specificity. J Exp Med. 1986 Apr 01; 163(4):812-25.
    View in: PubMed
    Score: 0.021
  25. Functional surface structures on human natural killer cells. Klin Wochenschr. 1985 Dec 02; 63(23):1189-200.
    View in: PubMed
    Score: 0.021
  26. Specific release of proteoglycans from human natural killer cells during target lysis. Nature. 1985 Nov 21-27; 318(6043):289-91.
    View in: PubMed
    Score: 0.021
  27. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. Blood. 1985 Oct; 66(4):961-6.
    View in: PubMed
    Score: 0.021
  28. Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. J Immunol. 1985 Aug; 135(2):1020-5.
    View in: PubMed
    Score: 0.020
  29. The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. J Immunol. 1985 Jul; 135(1):672-8.
    View in: PubMed
    Score: 0.020
  30. Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest. 1985 Mar; 75(3):932-43.
    View in: PubMed
    Score: 0.020
  31. Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood. 1984 Sep; 64(3):662-6.
    View in: PubMed
    Score: 0.019
  32. Identification of a 140-kDa activation antigen as a target structure for a series of human cloned natural killer cell lines. Eur J Immunol. 1984 Sep; 14(9):844-52.
    View in: PubMed
    Score: 0.019
  33. Natural killer-like function of activated T lymphocytes: differential blocking effects of monoclonal antibodies specific for a 90-kDa clonotypic structure. Cell Immunol. 1984 Jul; 86(2):381-92.
    View in: PubMed
    Score: 0.019
  34. Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. J Exp Med. 1983 Nov 01; 158(5):1547-60.
    View in: PubMed
    Score: 0.018
  35. Expression of MY7 antigen on myeloid precursor cells. Int J Cell Cloning. 1983 Apr; 1(1):33-48.
    View in: PubMed
    Score: 0.017
  36. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res. 1983 Mar; 43(3):1389-94.
    View in: PubMed
    Score: 0.017
  37. Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature. 1983 Jan 13; 301(5896):158-60.
    View in: PubMed
    Score: 0.017
  38. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
    View in: PubMed
    Score: 0.017
  39. Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med. 1983 Jan 01; 157(1):114-29.
    View in: PubMed
    Score: 0.017
  40. Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. J Immunol. 1982 Sep; 129(3):1299-305.
    View in: PubMed
    Score: 0.017
  41. Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest. 1982 Aug; 70(2):433-42.
    View in: PubMed
    Score: 0.016
  42. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res. 1982 Feb; 42(2):457-64.
    View in: PubMed
    Score: 0.016
  43. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest. 1981 Oct; 68(4):932-41.
    View in: PubMed
    Score: 0.016
  44. Expression of a 26,000-dalton glycoprotein on activated human T cells. Cell Immunol. 1981 Oct; 64(1):192-9.
    View in: PubMed
    Score: 0.016
  45. Human cell lines express multiple populations of Ia-like molecules. Hum Immunol. 1981 Aug; 3(1):67-76.
    View in: PubMed
    Score: 0.015
  46. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 1981 Jun; 57(6):1105-10.
    View in: PubMed
    Score: 0.015
  47. Surface antigens on malignant Sézary and T-CLL cells correspond to those of mature T cells. Blood. 1981 Mar; 57(3):526-30.
    View in: PubMed
    Score: 0.015
  48. Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody. J Immunol. 1981 Feb; 126(2):540-4.
    View in: PubMed
    Score: 0.015
  49. Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leuk Res. 1981; 5(6):491-5.
    View in: PubMed
    Score: 0.015
  50. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol. 1981; 12:187-225.
    View in: PubMed
    Score: 0.015
  51. Human leukemia-associated antigen: relation to a family of surface glycoproteins. J Immunol. 1980 Jun; 124(6):2794-9.
    View in: PubMed
    Score: 0.014
  52. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980 Mar; 55(3):395-402.
    View in: PubMed
    Score: 0.014
  53. Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. J Exp Med. 1979 Dec 01; 150(6):1472-82.
    View in: PubMed
    Score: 0.014
  54. Leukemia-associated antigens in ALL. Blood. 1979 Dec; 54(6):1240-8.
    View in: PubMed
    Score: 0.014
  55. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood. 1995 Feb 15; 85(4):1132-7.
    View in: PubMed
    Score: 0.010
  56. Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. J Clin Invest. 1994 Aug; 94(2):481-8.
    View in: PubMed
    Score: 0.009
  57. The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation. Transplantation. 1994 May 27; 57(10):1465-73.
    View in: PubMed
    Score: 0.009
  58. Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. J Immunol. 1992 Aug 15; 149(4):1199-203.
    View in: PubMed
    Score: 0.008
  59. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol. 1988 Jul 01; 141(1):131-8.
    View in: PubMed
    Score: 0.006
  60. Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood. 1987 Feb; 69(2):597-604.
    View in: PubMed
    Score: 0.006
  61. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells. J Clin Invest. 1986 Sep; 78(3):666-73.
    View in: PubMed
    Score: 0.005
  62. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. J Clin Invest. 1986 Mar; 77(3):977-84.
    View in: PubMed
    Score: 0.005
  63. Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis. J Exp Med. 1985 Dec 01; 162(6):1771-87.
    View in: PubMed
    Score: 0.005
  64. Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. J Immunol. 1985 Sep; 135(3):1746-51.
    View in: PubMed
    Score: 0.005
  65. Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Hum Immunol. 1981 Nov; 3(3):247-59.
    View in: PubMed
    Score: 0.004
  66. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981 Jan; 67(1):134-40.
    View in: PubMed
    Score: 0.004
  67. Comparative antigenic phenotypes of normal and leukemic hemopoietic precursor cells analysed with a "library" of monoclonal antibodies. Haematol Blood Transfus. 1981; 26:296-304.
    View in: PubMed
    Score: 0.004
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.